Add BrightSurf on Google Email

New models predict patterns of brain damage in dementia

Two studies published in Neuron have developed groundbreaking models that predict the landscape of degeneration in various forms of dementia. The models, which focus on structural and functional connectivity networks, suggest that dementias target specific networks of neurons linked by connectivity rather than spatial proximity.

SourceCell Press·JournalNeuron·DateMar 21, 2012

UCLA brain-imaging technique predicts who will suffer cognitive decline over time

A UCLA-developed brain-imaging tool detects abnormal protein deposits associated with Alzheimer's disease and tracks progression over time. The technique, using FDDNP-PET scans, predicts cognitive decline in individuals with mild cognitive impairment and normal aging, offering potential early detection and treatment of Alzheimer's.

Revised criteria could reclassify many with mild Alzheimer dementia

According to a study published in Archives of Neurology, revised criteria for mild cognitive impairment (MCI) may reclassify patients with very mild or mild Alzheimer's disease dementia. The new guidelines allow for more flexibility in defining functional independence, potentially affecting diagnostic approaches and treatment options.

SourceJAMA Network·JournalArchives of Neurology·DateFeb 6, 2012

Nursing home residents with dementia: Antidepressants are associated with increased risk of falling

A study found that nursing home residents with dementia who use average doses of selective serotonin reuptake inhibitors (SSRIs) are three times more likely to have an injurious fall than those who don't. The risk increases as people take higher doses of SSRIs, and combining them with hypnotic or sedative drugs further elevates the risk.

SourceWiley·JournalBritish Journal of Clinical Pharmacology·DateJan 18, 2012

Search for effective treatments for Alzheimer's Disease in patients with Down's syndrome goes on, after study shows memantine is ineffective

A new study published in The Lancet shows that memantine is ineffective for patients with Alzheimer's disease and Down syndrome aged 40 years and older. The drug was tested on 88 patients with or without dementia, but showed no significant improvement in cognition and function compared to a placebo group.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJan 9, 2012

A decade of research proves PET effectively detects dementia

A new review of imaging studies confirms that positron emission tomography (PET) safely and accurately detects dementia, including the most common form among the elderly, Alzheimer's disease. The study found that combining PET with a biomarker called 18F-FDG can pinpoint key areas of metabolic decline in the brain indicating dementia.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJan 6, 2012

MAKS: Drug-free prevention of dementia decline

Researchers found that a year-long Maks therapy, combining motor stimulation, cognitive exercises, and daily living activities, halted the progression of dementia in patients. This therapy showed similar results to cholinesterase inhibitors, but with twice as much effect on daily living tasks.

SourceBMC (BioMed Central)·JournalBMC Medicine·DateNov 30, 2011

The implications of disease coexistence

A new study published in Journal of Molecular Neuroscience emphasizes the significance of identifying 'overlap syndrome' between ALS and FTD, which can impact patient survival. The research also explores clinical characteristics, diagnostic criteria, and screening strategies for this syndrome.

SourceSpringer·JournalJournal of Molecular Neuroscience·DateNov 29, 2011

Nursing home quality scorecards don't tell the whole score

A new study finds that government scoring systems for nursing homes do not accurately evaluate the quality of care for residents with behavioral and psychological symptoms related to dementia. The study suggests that facilities with high numbers of cognitively impaired residents receive lower scores despite providing better care.

SourceIndiana University School of Medicine·JournalJournal of the American Medical Directors Association·DateNov 21, 2011

Trial shows that 2 main antidepressants prescribed for dementia patients with depression provide no benefit yet increased side effects

A recent trial found that sertraline and mirtazapine, commonly prescribed antidepressants for dementia patients with depression, provide no benefit but increase side effects. The study suggests that clinicians should reframe their approach to treating depression in Alzheimer's disease, considering alternative treatments.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJul 18, 2011